16.04.2015 • TopicscapabilitiesGEGE Healthcare

Rentschler Expands European Manufacturing Capabilities with GE Bioprocess Technologies

GE Healthcare Life Sciences has handed over its 1000th ÄKTAprocess to Rentschler Biotechnologie for use in the expanded biopharmaceutical manufacturing capabilities Rentschler has established in Laupheim, Germany.

The equipment supplied by GE features an automated process and manufacturing scale chromatography system. The offshoot of the US conglomerate said its biomanufacturing technologies such as the XDR 2000L bioreactor, the associated seed trains of 50, 200 and 500 L as well as the new ÄKTAprocess all play a key role in Rentschler's new single-use manufacturing line.

Peter Rogge, vice president of USP Production at Rentschler, said the new line "will further enhance our ability to deliver high quality projects for companies around the globe," adding that the GE technology is also enabling an increase in Europe of next-generation manufacturing capabilities.

 

 

 

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

most read

Photo
19.03.2025 • TopicsStrategy

Substances of Concern

The EU Chemicals Strategy for Sustainability (CSS) highlights the shift to a hazard-centric approach in EU chemical regulation, emphasizing 'Substance of Concern' over risk-based measures.

Photo
14.05.2025 • TopicsPharma

Pharma Outlook 2025

The environment for pharma in 2025 is diverse and challenging: New treatment options are being brought to market in ever shorter cycles.